Home Blog of Signal Transduction Metabolism IDO/TDO

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

IDO/TDO

IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer

4 views | Aug 19 2022

Meri Sieviläinen et al. revealed the subpopulation of lymphocytes responsible for the increases in specific serum cytokines after ICI treatment. [Read the Full Post]

Expression, purification, and kinetic characterization of the human strep-IDO1

4 views | Aug 19 2022

Dilizhatai Saimi et al. thought that purified human strep-IDO1 using the protocol described in the study could be used for further biochemical and structural analyses, which might facilitate functional research and further drug screening study on IDO1. [Read the Full Post]

The role of RIPK1 mediated cell death in acute on chronic liver failure

383 views | Dec 24 2021

Takayuki Kondo et al. thought that inhibition of RIPK1 was a potential novel therapeutic approach to prevent progression of susceptible patients from no ACLF to ACLF. [Read the Full Post]

Pharmacokinetics of S-epacadostat, an indoleamine 2,3-dioxygenase 1 inhibitor, in dog plasma and identification of its metabolites in vivo and in vitro

334 views | Sep 24 2021

Yumu Zhang et al. thought that substituting the nitrogen with sulfur affected the metabolism of the adjacent alkyl side chain. [Read the Full Post]

Overcoming Chemoimmunotherapy-Induced Immunosuppression by Assemblable and Depot Forming Immune Modulating Nanosuspension

365 views | Sep 24 2021

Seung Mo Jin et al. found that local administration of AIMS increased T cell infiltration in both local and distant tumors and significantly inhibited the metastasis of tumors to the lung. [Read the Full Post]

Synergistic Utilization of Necrostatin-1 and Z-VAD-FMK Efficiently Promotes the Survival of Compression-Induced Nucleus Pulposus Cells via Alleviating Mitochondrial Dysfunction

559 views | Jan 03 2021

Songfeng Chen et al. found that the synergistic utilization of Necrostatin-1 and Z-VAD-FMK was a very worthwhile solution in preventing compression-mediated NP cells death, which might be largely attributed to restored mitochondrial function. [Read the Full Post]

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

354 views | Sep 17 2020

Souvik Dey et al. found that the in vivo antitumor effects demonstrated with IDO1-based vaccines via targeting of the tumor microenvironment highlighted the utility of mouse models for further exploration and refinement of this novel vaccine-based approach to IDO1-directed cancer therapy and its potential to improve patient response rates to anti-PD1 therapy. [Read the Full Post]

Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma

396 views | Sep 17 2020

Sean Hacking et al. supported the theoretical foundation for targeting PD-L1 and IDO-1 in CRC, which now needed verification in well-designed robust clinical trials. [Read the Full Post]

MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer

566 views | Jan 17 2020

Venkateswaran N et al. proposed that limiting cellular kynurenine or its downstream targets could present a new strategy to reduce the proliferation of MYC-dependent cancer cells. [Read the Full Post]

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

534 views | Nov 25 2019

Beatty GL et al. showed that epacadostat was generally well tolerated, effectively normalized kynurenine levels, and produced maximal inhibition of IDO1 activity at doses of ≥100 mg BID. Studies investigating epacadostat in combination with other immunomodulatory drugs are ongoing. [Read the Full Post]